Although artificial intelligence in health has shown great promise, pressure is mounting for regulators around the world to act, as AI tools demonstrate potentially harmful outcomes.
Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
Cell and gene therapies represent an exciting and complex new treatment type, with the potential to treat a vast range of indications.
HSI Professor Joseph Doyle is interviewed on Freakomomics, M.D. podcast
By
Machine learning is a powerful form of artificial intelligence that is affecting every industry. Here’s what you need to know about its potential and limitations and how it’s being used.
By
A combination of AI and humans works best in tasks where humans outperform AI and in those that involve creating content.
By
The initiative is open to individuals, businesses and groups with the goal of developing a diverse, global community of problem solvers.
By
‘Those ad-hoc interactions are what people miss in today’s work-from-home environment.’
Members of the Student Sloan Healthcare Club are always responsible for this conference, but this year, the 19th, presented new complications since the event was held entirely online.
By
MIT Sloan School of Management’s Initiative for Health Systems Innovation (HSI) recently announced a formal collaboration with the Staten Island Performing Provider System (SI PPS).
